| Ytd | -91.66% | |
| 1y | -96.86% |
| Open | 0.40 | Prev Close | 0.45 | Low | 0.38 | High | 0.45 | Mkt Cap | 6.26M |
| Vol | 4.91M | Avg Vol | 7.41M | EPS | -3.85 | P/E | N/A | Forward P/E | -3.83 |
| Beta | 1.10 | Short Ratio | 3.71 | Inst. Own | 19.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 0.94 | 200-d Avg | 3.42 | 1yr Est | 3.34 |
Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-m
Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's a
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-mark
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regul
US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500
Gainers VolitionRX (AMEX:VNRX) shares increased by 102.2% to $0.69 during Thursday's pre-market
VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a
VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms acro
Salesforce Inc (NYSE: CRM) stock rose on good Q2 results and raised FY27 guidance, while other tech
112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboratio
112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboratio
Entitled "H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Second
Published in Critical Care Medicine , findings confirm high-predictive accuracy for severe sepsis ou
Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market
VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript
On Friday, VolitionRX (AMEX:VNRX) discussed second-quarter financial results during its earnings cal
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.85) per share which missed the analyst conse
Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30
This new lateral flow finger prick sample test could be used to rapidly identify high-risk patients
Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for NETosis Testing HE
Conference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global
Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis managemen
The clinical paper entitled "Prognostic value of circulating H3K27Me3-nucleosomes in newly diagn
HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"),
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces
HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition")
$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upo
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones HENDERSON, Nev., June 3, 2026 /P
Update Highlights 300% Q1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, and Active
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.97) per share which missed the analyst conse
Conference call to discuss financial and operational results scheduled for Friday, May 15 at 8:30 a
Conference call to take place on Friday, May 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces
The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 mil
HENDERSON, Nev., April 29, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"
HENDERSON, Nev., April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces
HC Wainwright & Co. analyst Yi Chen maintains VolitionRX (AMEX:VNRX) with a Buy and lowers th
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.05) per share which met the analyst consensu
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has secu